Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myeloid-Lymphoid Leukemia Protein | 23 | 2022 | 72 | 2.770 |
Why?
|
Leukemia, Myeloid, Acute | 18 | 2024 | 755 | 1.820 |
Why?
|
Oncogene Proteins, Fusion | 10 | 2022 | 128 | 1.560 |
Why?
|
Leukemia | 9 | 2017 | 318 | 1.540 |
Why?
|
Histone-Lysine N-Methyltransferase | 21 | 2023 | 154 | 1.400 |
Why?
|
DNA-Binding Proteins | 22 | 2019 | 1208 | 1.300 |
Why?
|
Proto-Oncogenes | 14 | 2005 | 61 | 1.240 |
Why?
|
Translocation, Genetic | 18 | 2016 | 265 | 1.180 |
Why?
|
Peptide Elongation Factors | 7 | 2005 | 28 | 1.170 |
Why?
|
Neoplasm Proteins | 9 | 2013 | 532 | 1.170 |
Why?
|
Transcription Factors | 20 | 2013 | 1555 | 1.140 |
Why?
|
Leukemia, Myeloid | 11 | 2012 | 249 | 1.100 |
Why?
|
Cell Transformation, Neoplastic | 7 | 2017 | 427 | 0.960 |
Why?
|
Gene Expression Regulation, Leukemic | 4 | 2011 | 90 | 0.840 |
Why?
|
Azacitidine | 8 | 2024 | 137 | 0.750 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 6 | 2024 | 76 | 0.730 |
Why?
|
Chromosomes, Human, Pair 11 | 16 | 2003 | 106 | 0.660 |
Why?
|
Antigens, CD34 | 2 | 2016 | 158 | 0.640 |
Why?
|
Sulfonamides | 6 | 2024 | 299 | 0.640 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2019 | 136 | 0.590 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 43 | 0.570 |
Why?
|
Anemia | 2 | 2020 | 128 | 0.550 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 2434 | 0.520 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2024 | 369 | 0.510 |
Why?
|
Proto-Oncogene Proteins | 6 | 2023 | 645 | 0.510 |
Why?
|
Transcriptional Elongation Factors | 10 | 2009 | 23 | 0.450 |
Why?
|
Homeodomain Proteins | 3 | 2013 | 535 | 0.450 |
Why?
|
Enhancer Elements, Genetic | 1 | 2013 | 266 | 0.400 |
Why?
|
Mitoxantrone | 3 | 2020 | 68 | 0.370 |
Why?
|
Mice | 21 | 2017 | 11313 | 0.360 |
Why?
|
Hematopoietic Stem Cells | 5 | 2019 | 292 | 0.350 |
Why?
|
Humans | 71 | 2024 | 86281 | 0.340 |
Why?
|
Acute Disease | 10 | 2013 | 824 | 0.310 |
Why?
|
Remission Induction | 9 | 2023 | 722 | 0.300 |
Why?
|
Myelodysplastic Syndromes | 6 | 2013 | 345 | 0.300 |
Why?
|
Aging | 1 | 2011 | 689 | 0.290 |
Why?
|
Cell Lineage | 2 | 2017 | 273 | 0.270 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 2 | 2018 | 10 | 0.270 |
Why?
|
Animals | 24 | 2017 | 26518 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 6 | 2013 | 43 | 0.260 |
Why?
|
Myeloproliferative Disorders | 2 | 2020 | 109 | 0.250 |
Why?
|
Lymphoma, T-Cell | 3 | 2013 | 48 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2013 | 1196 | 0.250 |
Why?
|
Gene Rearrangement | 7 | 2009 | 170 | 0.250 |
Why?
|
Coiled Bodies | 1 | 2003 | 2 | 0.230 |
Why?
|
Neutropenia | 1 | 2024 | 215 | 0.230 |
Why?
|
Transplantation Conditioning | 4 | 2013 | 373 | 0.230 |
Why?
|
Aged | 21 | 2022 | 18353 | 0.230 |
Why?
|
Transcriptional Activation | 3 | 2019 | 280 | 0.220 |
Why?
|
Dancing | 1 | 2022 | 1 | 0.220 |
Why?
|
Cytarabine | 3 | 2020 | 218 | 0.220 |
Why?
|
Thrombocytopenia | 2 | 2020 | 183 | 0.220 |
Why?
|
Consolidation Chemotherapy | 2 | 2018 | 22 | 0.210 |
Why?
|
Lymphoma | 4 | 2012 | 262 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 2351 | 0.200 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
Janus Kinase 2 | 2 | 2019 | 57 | 0.190 |
Why?
|
Febrile Neutropenia | 1 | 2020 | 14 | 0.190 |
Why?
|
Chromosomes, Human, Pair 19 | 3 | 2003 | 59 | 0.190 |
Why?
|
Aminopyridines | 1 | 2020 | 32 | 0.180 |
Why?
|
Tumor Cells, Cultured | 7 | 2011 | 1040 | 0.180 |
Why?
|
Molecular Sequence Data | 9 | 2002 | 3029 | 0.180 |
Why?
|
Amino Acid Sequence | 7 | 2002 | 2062 | 0.180 |
Why?
|
MicroRNAs | 3 | 2010 | 534 | 0.180 |
Why?
|
Triazines | 1 | 2020 | 47 | 0.180 |
Why?
|
Protein Binding | 5 | 2023 | 1454 | 0.180 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2020 | 51 | 0.180 |
Why?
|
Lymphoma, B-Cell | 2 | 2013 | 103 | 0.180 |
Why?
|
Retroviridae | 5 | 2013 | 78 | 0.180 |
Why?
|
Cloning, Molecular | 5 | 1997 | 646 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2019 | 589 | 0.170 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2010 | 199 | 0.170 |
Why?
|
Male | 30 | 2020 | 40860 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 589 | 0.170 |
Why?
|
Indazoles | 1 | 2019 | 68 | 0.170 |
Why?
|
Neoplasms, Second Primary | 3 | 2012 | 252 | 0.170 |
Why?
|
Pyrazines | 1 | 2019 | 84 | 0.170 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2018 | 49 | 0.170 |
Why?
|
Chromosome Deletion | 2 | 2016 | 228 | 0.160 |
Why?
|
Quercetin | 1 | 2018 | 3 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 859 | 0.160 |
Why?
|
Hematopoiesis | 1 | 2019 | 163 | 0.160 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2017 | 236 | 0.160 |
Why?
|
Transfection | 4 | 2007 | 895 | 0.160 |
Why?
|
Female | 28 | 2020 | 44405 | 0.160 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2023 | 121 | 0.160 |
Why?
|
Aged, 80 and over | 8 | 2020 | 6481 | 0.160 |
Why?
|
Mutation | 7 | 2023 | 3952 | 0.150 |
Why?
|
Cell Compartmentation | 1 | 1997 | 69 | 0.150 |
Why?
|
Nuclear Proteins | 3 | 2011 | 694 | 0.150 |
Why?
|
Zinc Fingers | 6 | 2010 | 56 | 0.140 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2016 | 110 | 0.140 |
Why?
|
HeLa Cells | 4 | 2010 | 498 | 0.140 |
Why?
|
Middle Aged | 19 | 2020 | 24957 | 0.140 |
Why?
|
Pneumonia | 2 | 2020 | 178 | 0.140 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2017 | 878 | 0.140 |
Why?
|
Prognosis | 6 | 2023 | 3669 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 5 | 2010 | 555 | 0.140 |
Why?
|
Repressor Proteins | 2 | 2013 | 403 | 0.130 |
Why?
|
Bone Marrow Transplantation | 2 | 1996 | 285 | 0.130 |
Why?
|
Chromosomes, Human, Pair 6 | 3 | 2007 | 125 | 0.130 |
Why?
|
Pyrimidines | 2 | 2016 | 370 | 0.130 |
Why?
|
Pyrazoles | 1 | 2016 | 153 | 0.130 |
Why?
|
Chromosome Aberrations | 5 | 2012 | 386 | 0.130 |
Why?
|
Patient Safety | 1 | 2018 | 212 | 0.130 |
Why?
|
Lymphocytes | 1 | 2017 | 461 | 0.130 |
Why?
|
Cytokines | 1 | 2019 | 775 | 0.130 |
Why?
|
Benzo(a)pyrene | 1 | 1994 | 5 | 0.130 |
Why?
|
RNA Polymerase II | 2 | 2009 | 55 | 0.130 |
Why?
|
Recurrence | 4 | 2020 | 1137 | 0.120 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 1994 | 79 | 0.120 |
Why?
|
Arteriosclerosis | 1 | 1994 | 113 | 0.120 |
Why?
|
RNA, Messenger | 9 | 2013 | 1975 | 0.120 |
Why?
|
Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2013 | 20 | 0.120 |
Why?
|
Oncogene Proteins v-myb | 1 | 2013 | 3 | 0.120 |
Why?
|
Transplantation, Homologous | 5 | 2017 | 996 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
Immunotherapy | 1 | 2018 | 627 | 0.110 |
Why?
|
Adult | 19 | 2024 | 25577 | 0.110 |
Why?
|
Cell Line, Tumor | 4 | 2012 | 2421 | 0.110 |
Why?
|
Aorta | 1 | 1994 | 280 | 0.110 |
Why?
|
Bronchiolitis Obliterans | 1 | 1992 | 31 | 0.110 |
Why?
|
Apoptosis | 4 | 2010 | 1678 | 0.110 |
Why?
|
Cell Line | 7 | 2009 | 2466 | 0.110 |
Why?
|
Superoxide Dismutase | 1 | 2012 | 177 | 0.100 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2011 | 23 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2020 | 7949 | 0.100 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 162 | 0.100 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2011 | 19 | 0.100 |
Why?
|
Blotting, Northern | 3 | 2002 | 256 | 0.100 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2011 | 46 | 0.100 |
Why?
|
Stem Cell Transplantation | 3 | 2012 | 183 | 0.100 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 3 | 1996 | 16 | 0.100 |
Why?
|
Erythropoietin | 1 | 2011 | 91 | 0.100 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 173 | 0.100 |
Why?
|
Hemoglobins | 1 | 2011 | 179 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 1996 | 348 | 0.100 |
Why?
|
Precancerous Conditions | 1 | 2012 | 196 | 0.100 |
Why?
|
Sequence Alignment | 2 | 2001 | 351 | 0.090 |
Why?
|
Follow-Up Studies | 3 | 2024 | 3616 | 0.090 |
Why?
|
Epigenomics | 1 | 2011 | 98 | 0.090 |
Why?
|
Adaptation, Physiological | 1 | 2012 | 306 | 0.090 |
Why?
|
Methylation | 1 | 2011 | 251 | 0.090 |
Why?
|
Caspase 3 | 1 | 2010 | 159 | 0.090 |
Why?
|
E1A-Associated p300 Protein | 1 | 2009 | 11 | 0.090 |
Why?
|
Immunohistochemistry | 5 | 2018 | 1752 | 0.090 |
Why?
|
Disease Models, Animal | 1 | 2016 | 2227 | 0.090 |
Why?
|
Genetic Loci | 1 | 2011 | 250 | 0.090 |
Why?
|
Prospective Studies | 4 | 2013 | 4194 | 0.090 |
Why?
|
Conserved Sequence | 2 | 2002 | 210 | 0.090 |
Why?
|
Adolescent | 11 | 2024 | 8968 | 0.090 |
Why?
|
Myeloid Progenitor Cells | 1 | 2009 | 15 | 0.090 |
Why?
|
Histones | 1 | 2011 | 309 | 0.090 |
Why?
|
Polymerase Chain Reaction | 3 | 2009 | 927 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 378 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2011 | 326 | 0.080 |
Why?
|
Up-Regulation | 1 | 2011 | 710 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 1680 | 0.080 |
Why?
|
Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
Disease-Free Survival | 3 | 2018 | 1203 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2009 | 1381 | 0.080 |
Why?
|
Chronic Disease | 1 | 2011 | 968 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 329 | 0.080 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2008 | 107 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 272 | 0.080 |
Why?
|
Melphalan | 2 | 2005 | 97 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2008 | 165 | 0.080 |
Why?
|
Vidarabine | 2 | 2005 | 141 | 0.080 |
Why?
|
Core Binding Factor beta Subunit | 1 | 2007 | 2 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2007 | 24 | 0.080 |
Why?
|
DNA Methylation | 2 | 2009 | 622 | 0.070 |
Why?
|
Chromosome Inversion | 1 | 2007 | 47 | 0.070 |
Why?
|
Prevalence | 1 | 2011 | 1239 | 0.070 |
Why?
|
Chromatin | 2 | 2022 | 378 | 0.070 |
Why?
|
Base Sequence | 7 | 2008 | 2329 | 0.070 |
Why?
|
Karnofsky Performance Status | 1 | 2006 | 40 | 0.070 |
Why?
|
Myosin Heavy Chains | 1 | 2007 | 88 | 0.070 |
Why?
|
Bone Marrow | 3 | 2008 | 434 | 0.070 |
Why?
|
Precision Medicine | 1 | 2011 | 394 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 916 | 0.070 |
Why?
|
Immune Complex Diseases | 1 | 2006 | 19 | 0.070 |
Why?
|
Karyotyping | 4 | 2011 | 250 | 0.070 |
Why?
|
Complement Factor H | 1 | 2006 | 34 | 0.070 |
Why?
|
Complement System Proteins | 1 | 2006 | 81 | 0.070 |
Why?
|
Meperidine | 1 | 1985 | 13 | 0.070 |
Why?
|
Genetic Vectors | 2 | 2013 | 438 | 0.070 |
Why?
|
Transcription, Genetic | 5 | 2009 | 1135 | 0.070 |
Why?
|
Inflammation | 1 | 2011 | 913 | 0.070 |
Why?
|
Blood Platelets | 1 | 2006 | 149 | 0.070 |
Why?
|
Dioxygenases | 2 | 2019 | 74 | 0.070 |
Why?
|
Young Adult | 4 | 2024 | 5961 | 0.070 |
Why?
|
Recombinant Proteins | 2 | 2008 | 1014 | 0.070 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1997 | 416 | 0.070 |
Why?
|
DNA, Neoplasm | 6 | 1996 | 265 | 0.070 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2005 | 12 | 0.070 |
Why?
|
Emergencies | 1 | 1985 | 113 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2006 | 253 | 0.060 |
Why?
|
Promoter Regions, Genetic | 5 | 2009 | 937 | 0.060 |
Why?
|
Binding Sites | 3 | 2002 | 1098 | 0.060 |
Why?
|
Cohort Studies | 1 | 2011 | 2759 | 0.060 |
Why?
|
Chromosome Mapping | 7 | 1996 | 1074 | 0.060 |
Why?
|
Kidney | 2 | 2010 | 1240 | 0.060 |
Why?
|
Retrospective Studies | 4 | 2024 | 8431 | 0.060 |
Why?
|
snRNP Core Proteins | 1 | 2003 | 9 | 0.060 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2004 | 138 | 0.060 |
Why?
|
Epigenesis, Genetic | 2 | 2022 | 476 | 0.060 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2003 | 20 | 0.060 |
Why?
|
Gene Expression Regulation | 2 | 2009 | 1917 | 0.060 |
Why?
|
Survival Analysis | 3 | 2018 | 1536 | 0.060 |
Why?
|
Immunosorbent Techniques | 1 | 2002 | 13 | 0.060 |
Why?
|
Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
Sequence Homology | 1 | 2002 | 28 | 0.060 |
Why?
|
Seizures | 1 | 1985 | 293 | 0.060 |
Why?
|
Aspartic Acid | 1 | 2002 | 64 | 0.060 |
Why?
|
Genes | 2 | 1994 | 305 | 0.060 |
Why?
|
Genes, Regulator | 1 | 2022 | 65 | 0.060 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2003 | 58 | 0.060 |
Why?
|
Serine | 1 | 2002 | 99 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2013 | 1537 | 0.050 |
Why?
|
Autoantigens | 1 | 2003 | 127 | 0.050 |
Why?
|
Glutamic Acid | 1 | 2002 | 152 | 0.050 |
Why?
|
Biomarkers | 2 | 2019 | 1709 | 0.050 |
Why?
|
Phosphoproteins | 1 | 2003 | 253 | 0.050 |
Why?
|
Precipitin Tests | 1 | 2001 | 108 | 0.050 |
Why?
|
Administration, Oral | 2 | 2018 | 683 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 1958 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2002 | 460 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 72 | 0.050 |
Why?
|
Leukopenia | 1 | 2020 | 65 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2002 | 579 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2006 | 2810 | 0.050 |
Why?
|
Down-Regulation | 1 | 2002 | 504 | 0.050 |
Why?
|
Core Binding Factors | 2 | 2011 | 12 | 0.050 |
Why?
|
Gene Transfer Techniques | 1 | 2000 | 152 | 0.050 |
Why?
|
Ethylnitrosourea | 2 | 2012 | 30 | 0.040 |
Why?
|
Survival Rate | 2 | 2018 | 1856 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 1997 | 307 | 0.040 |
Why?
|
RNA | 1 | 2003 | 560 | 0.040 |
Why?
|
Comorbidity | 2 | 2017 | 943 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2004 | 977 | 0.040 |
Why?
|
Expert Testimony | 1 | 2018 | 46 | 0.040 |
Why?
|
Hematologic Diseases | 2 | 2012 | 79 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2018 | 76 | 0.040 |
Why?
|
Cell Survival | 2 | 2012 | 966 | 0.040 |
Why?
|
Graft Rejection | 1 | 2004 | 1064 | 0.040 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2019 | 112 | 0.040 |
Why?
|
Tretinoin | 1 | 2018 | 125 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2018 | 81 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2002 | 853 | 0.040 |
Why?
|
Topoisomerase II Inhibitors | 2 | 1996 | 26 | 0.040 |
Why?
|
Induction Chemotherapy | 1 | 2018 | 147 | 0.040 |
Why?
|
Trans-Activators | 1 | 2000 | 429 | 0.040 |
Why?
|
Cell Self Renewal | 1 | 2017 | 18 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2018 | 228 | 0.040 |
Why?
|
Cellular Microenvironment | 1 | 2017 | 27 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2018 | 356 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1997 | 68 | 0.040 |
Why?
|
Embryonic and Fetal Development | 1 | 1997 | 72 | 0.040 |
Why?
|
DNA Primers | 3 | 2008 | 542 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2018 | 128 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 270 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 429 | 0.040 |
Why?
|
Child, Preschool | 5 | 1996 | 3608 | 0.040 |
Why?
|
Graft vs Host Disease | 2 | 2005 | 364 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2010 | 547 | 0.040 |
Why?
|
Embryo, Mammalian | 1 | 1997 | 207 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2018 | 166 | 0.040 |
Why?
|
Phosphorylation | 1 | 2019 | 1101 | 0.040 |
Why?
|
Proteins | 1 | 2002 | 777 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1996 | 19 | 0.040 |
Why?
|
Genes, p53 | 1 | 2016 | 109 | 0.040 |
Why?
|
Adenine | 1 | 2016 | 85 | 0.040 |
Why?
|
Disease Management | 1 | 2018 | 327 | 0.040 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1995 | 14 | 0.030 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1995 | 5 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2020 | 1822 | 0.030 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1995 | 86 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 1708 | 0.030 |
Why?
|
RNA, Neoplasm | 3 | 2007 | 87 | 0.030 |
Why?
|
Pilot Projects | 1 | 2018 | 837 | 0.030 |
Why?
|
Species Specificity | 1 | 1997 | 678 | 0.030 |
Why?
|
Piperidines | 1 | 2016 | 181 | 0.030 |
Why?
|
Methylcholanthrene | 1 | 1994 | 10 | 0.030 |
Why?
|
Microsomes | 1 | 1994 | 35 | 0.030 |
Why?
|
Gene Library | 1 | 1994 | 130 | 0.030 |
Why?
|
Biotransformation | 1 | 1994 | 50 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 877 | 0.030 |
Why?
|
Enzyme Induction | 1 | 1994 | 88 | 0.030 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1994 | 79 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 1994 | 100 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 100 | 0.030 |
Why?
|
Organ Specificity | 1 | 1994 | 257 | 0.030 |
Why?
|
Gene Deletion | 1 | 1995 | 328 | 0.030 |
Why?
|
Radiotherapy | 1 | 1996 | 326 | 0.030 |
Why?
|
Patient Selection | 1 | 2018 | 685 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 1842 | 0.030 |
Why?
|
Fetus | 1 | 1994 | 226 | 0.030 |
Why?
|
X Chromosome | 1 | 1994 | 152 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2006 | 857 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2018 | 1932 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1993 | 65 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 1168 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2012 | 3087 | 0.030 |
Why?
|
Alkylating Agents | 1 | 2012 | 32 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2013 | 65 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1994 | 302 | 0.030 |
Why?
|
Mercaptoethylamines | 1 | 2012 | 52 | 0.030 |
Why?
|
Child | 5 | 1996 | 6913 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2012 | 188 | 0.030 |
Why?
|
Genetic Markers | 1 | 1993 | 476 | 0.030 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 24 | 0.030 |
Why?
|
Genomic Instability | 1 | 2012 | 79 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 3233 | 0.030 |
Why?
|
Gene Expression | 3 | 2004 | 1281 | 0.030 |
Why?
|
Prednisone | 1 | 1992 | 255 | 0.030 |
Why?
|
Liver | 1 | 1997 | 1229 | 0.030 |
Why?
|
Mutagenesis, Insertional | 1 | 2012 | 111 | 0.030 |
Why?
|
Syndrome | 1 | 1992 | 446 | 0.030 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 34 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 1994 | 1214 | 0.030 |
Why?
|
United States | 1 | 2024 | 6637 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1993 | 261 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2011 | 79 | 0.020 |
Why?
|
Genes, ras | 1 | 2011 | 96 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 181 | 0.020 |
Why?
|
Chromosome Banding | 3 | 1995 | 74 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2013 | 388 | 0.020 |
Why?
|
Caspase Inhibitors | 1 | 2010 | 33 | 0.020 |
Why?
|
K562 Cells | 1 | 2010 | 43 | 0.020 |
Why?
|
Risk | 1 | 2012 | 673 | 0.020 |
Why?
|
Smoking | 1 | 1994 | 605 | 0.020 |
Why?
|
Chromosome Disorders | 3 | 1995 | 114 | 0.020 |
Why?
|
Mitogens | 1 | 2009 | 64 | 0.020 |
Why?
|
Consensus Sequence | 2 | 2002 | 64 | 0.020 |
Why?
|
Multigene Family | 1 | 2010 | 202 | 0.020 |
Why?
|
Restriction Mapping | 3 | 1993 | 157 | 0.020 |
Why?
|
Cyclophilins | 1 | 2008 | 8 | 0.020 |
Why?
|
Histone Deacetylase 1 | 1 | 2008 | 13 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2009 | 152 | 0.020 |
Why?
|
Infant | 4 | 1996 | 3036 | 0.020 |
Why?
|
Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2008 | 50 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2008 | 63 | 0.020 |
Why?
|
Imatinib Mesylate | 1 | 2008 | 126 | 0.020 |
Why?
|
Rats | 1 | 1994 | 3984 | 0.020 |
Why?
|
Peptide Mapping | 1 | 2007 | 26 | 0.020 |
Why?
|
Benzamides | 1 | 2008 | 226 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 52 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2008 | 328 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 1305 | 0.020 |
Why?
|
Gene Silencing | 1 | 2007 | 172 | 0.020 |
Why?
|
Piperazines | 1 | 2008 | 272 | 0.020 |
Why?
|
Myoclonus | 1 | 1985 | 15 | 0.020 |
Why?
|
Hamartoma | 1 | 1985 | 31 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 2885 | 0.020 |
Why?
|
Alemtuzumab | 1 | 2005 | 83 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2005 | 84 | 0.020 |
Why?
|
DNA, Complementary | 2 | 1996 | 393 | 0.020 |
Why?
|
COS Cells | 1 | 2005 | 166 | 0.020 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.020 |
Why?
|
Oncogenes | 1 | 2004 | 88 | 0.020 |
Why?
|
Brain | 1 | 1994 | 2211 | 0.020 |
Why?
|
DNA Probes | 2 | 1993 | 77 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2004 | 509 | 0.010 |
Why?
|
Herpes Simplex Virus Protein Vmw65 | 1 | 2002 | 5 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2002 | 129 | 0.010 |
Why?
|
Luciferases | 1 | 2002 | 118 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2009 | 1611 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2002 | 303 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2002 | 266 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2006 | 1918 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2007 | 1571 | 0.010 |
Why?
|
CREB-Binding Protein | 1 | 2000 | 16 | 0.010 |
Why?
|
Rabbits | 1 | 2002 | 636 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 1985 | 620 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2005 | 929 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2002 | 1047 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2005 | 1376 | 0.010 |
Why?
|
Neoplasms | 1 | 1993 | 2889 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2002 | 724 | 0.010 |
Why?
|
Teniposide | 1 | 1996 | 6 | 0.010 |
Why?
|
Centromere | 1 | 1996 | 26 | 0.010 |
Why?
|
Risk Factors | 1 | 2006 | 5397 | 0.010 |
Why?
|
Etoposide | 1 | 1996 | 196 | 0.010 |
Why?
|
Telomere | 1 | 1996 | 107 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 1994 | 48 | 0.010 |
Why?
|
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 33 | 0.010 |
Why?
|
Codon | 1 | 1994 | 124 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1994 | 135 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1996 | 276 | 0.010 |
Why?
|
Alternative Splicing | 1 | 1995 | 201 | 0.010 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 1993 | 8 | 0.010 |
Why?
|
Leukemia, Lymphoid | 1 | 1993 | 72 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1993 | 72 | 0.010 |
Why?
|
Introns | 1 | 1994 | 289 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1993 | 129 | 0.010 |
Why?
|
CD3 Complex | 1 | 1993 | 135 | 0.010 |
Why?
|
RNA Splicing | 1 | 1994 | 142 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1992 | 987 | 0.010 |
Why?
|
Drosophila | 1 | 1995 | 494 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1995 | 2369 | 0.010 |
Why?
|